Insight Molecular Diagnostics Inc (IMDX) Stock Price, Quote & News

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 949 409 7600

Website: imdxinc.com

Address:

2 International Plaza Dr., Suite 510, Nashville, United States

jackedmund99 Oct. 3 at 6:50 PM

$IMDX Fox bitch just talked about biotech and oncology stocks being bought up by big farmer. Lotta Consolidation coming as big farmer needs to buy growth so they’ll be coming after smaller stocks

1 · Reply

prismmarketview Sep. 24 at 3:26 PM

(Nasdaq: $IMDX) Insight Molecular Diagnostics is showcasing its GraftAssure™ transplant rejection technology at conferences in Singapore & Orlando. With FDA submission of GraftAssureDx planned by year-end, iMDx is advancing in-house dd-cfDNA testing for kidney transplant care. https://prismmarketview.com/insight-molecular-diagnostics-showcases-kidney-transplant-testing-leadership-at-global-conferences/

0 · Reply

JohnPDaly Sep. 24 at 2:38 PM

$IMDX Sneaky little 100 bagger? 🤷‍♂️

0 · Reply

JohnPDaly Sep. 19 at 8:18 PM

$IMDX heafty raises.

1 · Reply

jackedmund99 Sep. 16 at 6:40 PM

$IMDX this company starting to come around the problem is it’s got a couple years worth of bad results. It’s got approved to the market that it’s turning, but it’s doing that and when the street does wake up, we will see a double digit stock easily.

1 · Reply

prismmarketview Sep. 16 at 2:57 PM

(Nasdaq: $IMDX) Insight Molecular Diagnostics is advancing kidney transplant rejection care with two major milestones: launching a 5,000-patient real-world registry and enrolling the first patient in its pivotal GraftAssureDx clinical trial. Both initiatives support FDA submission in 2025 and a planned 2026 launch. https://prismmarketview.com/insight-molecular-diagnostics-advances-kidney-transplant-rejection-programs-with-new-registry-and-clinical-trial-enrollment/

0 · Reply

cache1b Sep. 12 at 2:44 AM

$IMDX @JohnPDaly @LefDeppard On review overnight, bid 2.80 ask 3.30. You can drive a truck through that spread. What's that all about?

2 · Reply

JohnPDaly Sep. 11 at 4:50 PM

$IMDX Here I am alone in the stock.

1 · Reply

JohnPDaly Sep. 11 at 2:51 PM

$MDWD $LCTX $IMDX bought more and a little Bitty as well !

0 · Reply

cache1b Sep. 11 at 7:44 AM

$IMDX http://stocktwits.com/cache1b/message/628264981 @RUNNINWILD Thanks.... @LefDeppard

0 · Reply

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 8, 2025, 7:15 AM EDT - 26 days ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:00 AM EDT - 26 days ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Aug 26, 2025, 4:05 PM EDT - 5 weeks ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 11, 2025, 4:05 PM EDT - 7 weeks ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 4, 2025, 4:05 PM EDT - 2 months ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Jul 30, 2025, 4:05 PM EDT - 2 months ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 28, 2025, 4:05 PM EDT - 2 months ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jun 23, 2025, 4:05 PM EDT - 3 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

May 19, 2025, 4:05 PM EDT - 4 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 12, 2025, 11:32 PM EDT - 5 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 5 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

May 7, 2025, 4:10 PM EDT - 5 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Apr 30, 2025, 8:30 AM EDT - 5 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 29, 2025, 8:30 AM EDT - 5 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Mar 24, 2025, 6:53 PM EDT - 6 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 7 months ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Feb 11, 2025, 8:30 AM EST - 8 months ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 8, 2025, 8:30 AM EST - 9 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 6, 2025, 4:05 PM EST - 9 months ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Nov 12, 2024, 8:52 PM EST - 11 months ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:45 PM EST - 11 months ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 2 years ago

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Oncocyte Presents New Data at AACR

Apr 12, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Announces Reduction in Force

Apr 7, 2023, 8:24 AM EDT - 2 years ago

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Apr 3, 2023, 11:40 AM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 5:00 PM EDT - 2 years ago

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 9:00 AM EST - 2 years ago

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Feb 22, 2023, 8:00 AM EST - 2 years ago

Oncocyte Completes Razor Genomics Transaction

Dec 16, 2022, 8:19 AM EST - 3 years ago

Oncocyte cuts 40% of staff

jackedmund99 Oct. 3 at 6:50 PM

$IMDX Fox bitch just talked about biotech and oncology stocks being bought up by big farmer. Lotta Consolidation coming as big farmer needs to buy growth so they’ll be coming after smaller stocks

1 · Reply

prismmarketview Sep. 24 at 3:26 PM

0 · Reply

JohnPDaly Sep. 24 at 2:38 PM

$IMDX Sneaky little 100 bagger? 🤷‍♂️

0 · Reply

JohnPDaly Sep. 19 at 8:18 PM

$IMDX heafty raises.

1 · Reply

jackedmund99 Sep. 16 at 6:40 PM

1 · Reply

prismmarketview Sep. 16 at 2:57 PM

0 · Reply

cache1b Sep. 12 at 2:44 AM

$IMDX @JohnPDaly @LefDeppard On review overnight, bid 2.80 ask 3.30. You can drive a truck through that spread. What's that all about?

2 · Reply

JohnPDaly Sep. 11 at 4:50 PM

$IMDX Here I am alone in the stock.

1 · Reply

JohnPDaly Sep. 11 at 2:51 PM

$MDWD $LCTX $IMDX bought more and a little Bitty as well !

0 · Reply

cache1b Sep. 11 at 7:44 AM

$IMDX http://stocktwits.com/cache1b/message/628264981 @RUNNINWILD Thanks.... @LefDeppard

0 · Reply

cache1b Sep. 11 at 7:42 AM

$IMDX @JohnPDaly First post, ass dial Got Feedback, too funny... Thanks! Looked at chart, when the universe knocks, you got to open the door. Yah. I see it, $4 next couple of months, $10 real quick right after. Nice chart, would like more volume.... Tty on upmove/volume.

0 · Reply

NVDAMillionaire Sep. 11 at 6:28 AM

$IMDX Excellent article that nails exactly where IMDX stands right now. So if you want to update your IMDX knowledge or get acquainted with IMDX, this is a must read. https://beyondspx.com/quote/IMDX/analysis/insight-molecular-diagnostics-unlocking-transplant-value-with-a-kitted-revolution-nasdaq-imdx

0 · Reply

cache1b Sep. 10 at 7:09 PM

$IMDX 0,¹22²33³²⅘⁵555⁵5556677⅞)}++⁶(<{>)>a lot 8?⁸77-553317777111

2 · Reply

jackedmund99 Sep. 10 at 6:02 PM

$IMDX hopefully the market is waking up to the real promises that this company has- market cap of 500 mill now is not unreasonable

1 · Reply

JohnPDaly Sep. 10 at 4:26 PM

$IMDX

0 · Reply

JohnPDaly Sep. 10 at 4:07 PM

$IMDX 👀

0 · Reply

JohnPDaly Sep. 9 at 8:54 PM

$IMDX once again, as the only one here, I want to congratulate myself. Well, done.

0 · Reply

BioTuesdays Sep. 8 at 4:21 PM

$IMDX has announced a positive strategic update and novel registry to gather real-world data on patient experiences and outcomes concerning its flagship kidney transplant rejection assay. https://biotuesdays.com/2025/09/08/imdx-launches-novel-registry-database-reports-positive-strategic-update/

1 · Reply

JohnPDaly Sep. 8 at 11:29 AM

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2025/09-08-2025-120207162

0 · Reply

AlphaProspector Aug. 27 at 9:42 AM

$IMDX volatile swings, risk management key here.

0 · Reply

RUNNINWILD Aug. 26 at 3:49 PM

$IMDX https://stocks.apple.com/ADl9wLbtGQWeGyrCpnhzRCw

0 · Reply

JohnPDaly Aug. 20 at 1:46 PM

$IMDX

0 · Reply

Market Cap	95.88M
Revenue (ttm)	1.88M
Net Income (ttm)	-60.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,226.60%
Debt to Equity Ratio	0.00

Volume	22,700
Avg Vol	35,574
Day's Range	N/A - N/A
Shares Out	28.62M
Stochastic %K	61%
Beta	1.24
Analysts	Sell
Price Target	$5.42